BiVictriX Therapeutics Limited founder and CEO Tiffany Thorn speaks with Proactive's Stephen Gunnion about the company's decision to delist from AIM and the promising advancements in their oncology pipeline. Thorn explained the rationale behind the move, stating, "AIM's not really given us the platform... so we're undervalued." She emphasised the need to accelerate asset development as a private company. Thorn highlighted key milestones, including the recent positive preclinical data from their lead solid tumorr program, BVX002, targeting ovarian cancer. Thorn described the data as "astonishingly positive," noting that the results surpassed expectations and compared favourably to competitor ADCs. She also outlined plans for further tumour model studies, including breast cancer, and ongoing developments in their proprietary library targeting multiple tumour indications. Watch the full video for insights into BiVictriX's next steps and how the company aims to maintain its competitive edge in the ADC space. Don't forget to give this video a like, subscribe to the channel, and enable notifications for more updates from Proactive. #BiVictriX #TiffanyThorn #AIMDelisting #ADC #Biotech #OvarianCancer #BVX002 #Oncology #Pharma#ProactiveInvestors #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnewstoday